# Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

> **NCT05036421** · PHASE3 · COMPLETED · sponsor: **Ain Shams University** · enrollment: 18 (actual)

## Conditions studied

- Pharmacogenomic
- Pharmacokinetics

## Interventions

- **DRUG:** Empagliflozin 10 milligram

## Key facts

- **NCT ID:** NCT05036421
- **Lead sponsor:** Ain Shams University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2022-05-20
- **Final completion:** 2022-05-20
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036421

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036421, "Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05036421. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*